The recent study by Turner et al. (2023) on hormone receptor-positive advanced breast cancer showcased significant improvements in progression-free and overall survival with capivasertib, cementing its status as a potent therapeutic agent [6]. This evidence concerns the gene NR4A1 and breast carcinoma.